MANKIND
MANKIND stock
MANKIND is showing a constructive news setup around Pharmaceuticals, with 9 recent stories and improving sentiment breadth.
MANKIND stock
MANKIND is showing a constructive news setup around Pharmaceuticals, with 9 recent stories and improving sentiment breadth.
MANKIND has built a constructive coverage cluster in the last 21 days. The strongest recurring theme is Pharmaceuticals, while the current weighted impact score is +26 from 6 bullish, 2 bearish, and 1 neutral stories across 3 sources.
MANKIND is last saved at ₹2,400 with a day move of +0.00%. That quote should be read with the article tape: a positive headline only matters if price, volume, and follow-through confirm it; a negative headline matters more when it keeps repeating across multiple publishers.
This is the first public financial report for Mankind Pharma. The company made ₹3230 crore in sales and ₹381 crore in profit. This information helps us understand how much money the company is making and keeping. This hub keeps the permanent stock view separate from short-lived article pages, so search engines and users get one accumulated view instead of scattered programmatic summaries.
Mint · 11 days ago · 2 min read
Economic Times · 13 days ago · 2 min read
Economic Times · 15 days ago · 2 min read
Mint · 19 days ago · 2 min read
Economic Times · 19 days ago · 2 min read
How MANKIND stacks against related names in this news cluster
MANKIND has appeared across 9 recent stories from 3 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.
MANKIND coverage is currently leaning bullish, with 6 bullish, 2 bearish, and 1 neutral analyzed stories in the recent window.
Recent MANKIND coverage is clustering around Pharmaceuticals and Pharma. Related names showing up alongside MANKIND include CIPLA, TORNTPHARM, ACUTAAS.
Use this page as a coverage hub for MANKIND: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.
5 recent mentions linked to MANKIND
TopicPharma2 recent mentions linked to MANKIND
StockCIPLARelated news cluster with 2 links
Latest storyMixed Pharma Q2: Acutaas, Mankind, Ipca Labs Favored; DRL, CiplaPharma sector performance is influenced by currency, input costs, and regulatory environment. Q2 res